WO2022090561A1 - Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids - Google Patents
Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids Download PDFInfo
- Publication number
- WO2022090561A1 WO2022090561A1 PCT/EP2021/080315 EP2021080315W WO2022090561A1 WO 2022090561 A1 WO2022090561 A1 WO 2022090561A1 EP 2021080315 W EP2021080315 W EP 2021080315W WO 2022090561 A1 WO2022090561 A1 WO 2022090561A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- composition
- composition according
- substrate
- compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 12
- 230000002496 gastric effect Effects 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 14
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004615 ingredient Substances 0.000 claims abstract description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- 235000010755 mineral Nutrition 0.000 claims abstract description 9
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000005770 Eugenol Substances 0.000 claims abstract description 7
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002217 eugenol Drugs 0.000 claims abstract description 7
- 229930153442 Curcuminoid Natural products 0.000 claims abstract description 6
- 239000005844 Thymol Substances 0.000 claims abstract description 6
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims abstract description 6
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000007746 carvacrol Nutrition 0.000 claims abstract description 6
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930004725 sesquiterpene Natural products 0.000 claims abstract description 6
- 229960000790 thymol Drugs 0.000 claims abstract description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 241000196324 Embryophyta Species 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 16
- 244000223014 Syzygium aromaticum Species 0.000 claims description 13
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 13
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 11
- 240000002657 Thymus vulgaris Species 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000001585 thymus vulgaris Substances 0.000 claims description 11
- 240000002234 Allium sativum Species 0.000 claims description 9
- 244000273928 Zingiber officinale Species 0.000 claims description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 9
- 235000003373 curcuma longa Nutrition 0.000 claims description 9
- 235000004611 garlic Nutrition 0.000 claims description 9
- 235000008397 ginger Nutrition 0.000 claims description 9
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 8
- 235000017803 cinnamon Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 244000163122 Curcuma domestica Species 0.000 claims description 7
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 235000013976 turmeric Nutrition 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 6
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 6
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 6
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 5
- -1 sesquiterpene compounds Chemical class 0.000 claims description 5
- 150000003464 sulfur compounds Chemical class 0.000 claims description 5
- 235000020230 cinnamon extract Nutrition 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- 244000080208 Canella winterana Species 0.000 claims description 2
- 235000008499 Canella winterana Nutrition 0.000 claims description 2
- 239000006000 Garlic extract Substances 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 229940017545 cinnamon bark Drugs 0.000 claims description 2
- 238000010908 decantation Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 235000020706 garlic extract Nutrition 0.000 claims description 2
- 229940002508 ginger extract Drugs 0.000 claims description 2
- 235000020708 ginger extract Nutrition 0.000 claims description 2
- 238000005470 impregnation Methods 0.000 claims description 2
- 229940052016 turmeric extract Drugs 0.000 claims description 2
- 235000020240 turmeric extract Nutrition 0.000 claims description 2
- 239000008513 turmeric extract Substances 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims 1
- 235000009973 maize Nutrition 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 16
- 231100000397 ulcer Toxicity 0.000 description 16
- 241000283086 Equidae Species 0.000 description 13
- 241000283073 Equus caballus Species 0.000 description 9
- 230000035876 healing Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000835 fiber Substances 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 241000150100 Margo Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010038001 Rebound effect Diseases 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to a composition for gastric treatment, in particular for the treatment of gastric ulcers.
- composition according to the invention can be used for the gastric treatment of other animals, or even of human beings.
- Gastric ulcers are lesions that appear on the stomach wall. When ulcers come in contact with gastric juice, they can be painful. These lesions can have influences on the performance of equines as well as their mood.
- Gastrogard® in the form of a paste, is commonly used for the treatment of ulcers.
- This product whose active substance is omeprazole, is certainly effective, but it has side effects such as an imbalance of the intestinal flora, bone fragility, poor assimilation of nutrients, a significant risk of rebound effect and therefore more serious recurrences. In addition, this product is very expensive.
- the commercial products Ekygard Flash and Ekygard are compositions containing bicarbonates, Althaea officinalis, hyaluronic acid and also eugenol and curcumin and proanthocyanidins and cinnamaldehyde and are also used for the prevention of ulcers of equines. They are however not entirely natural and are also expensive.
- Twydil® congressare which is a composition based on fatty acids from refining, fibers of the glucosamine type, magnesium trisilicate.
- This product is used for its curative and preventive actions of ulcers. It acts as a gastric tampon and helps healing but it is not active enough.
- This product contains palm oil and chemical preservatives. Palm oil is negatively known for all environmental reasons and chemical preservatives have a negative influence on the health of mammals in the long run, as well as the environment.
- Green clay is certainly very economical to use, but it can cause colic and acts more like a gastric bandage and therefore does not really help in the active healing of ulcers.
- the product marketed under the name Serenitude is a solution based on chicory and brewer's yeast which helps the development of flora in the stomach, thus preventing the appearance of ulcers.
- this product does not cure ulcers that have already appeared. Indeed, yeasts behave like probiotics, but if the ground (mucous membranes) is not balanced for the probiotics to live, then the addition of these prebiotics will only be useful temporarily and that only on condition that bacteria lactobacillus type are present in number. In other words, its effectiveness remains relative.
- the object of the present invention is to at least partially meet this need.
- the object of the invention is a composition for gastric treatment, in particular for the treatment of gastric ulcers, comprising the following natural ingredients:
- the composition also comprises, as natural ingredient, a cinnamon extract.
- the cinnamon extract containing at least 10% by weight of proanthocyanins and/or at least 10% by weight of cinnamaldehyde, preferably from 10 to 20% by weight of cinnamaldehyde.
- the substances are advantageously extracted, after selection of their content of active compounds, in the following plants:
- composition according to the invention comprises:
- a clove extract containing at least 10% by weight of eugenol and at least 1% by weight of ethyl acetate
- turmeric extract containing at least 2% by weight of curcuminoid compounds
- ginger extract containing at least 5% by weight of sesquiterpene compounds
- thyme extract containing at least 0.5% by weight of thymol and at least 0.5% by weight of carvacrol
- composition may be a colloidal solution or in solid form, preferably in powder form, if necessary compacted in the form of cachet(s).
- composition according to the present invention based on natural ingredients or of natural origin contributes to the healing of ulcers which can be grade 1 to 3 on a scale of 4 or 5. Indeed, the composition according to the present invention has healing properties, anti-inflammatory, balancing the flora and normalizing the pH. This effect is obtained by the synergy of the compounds used whose extractions come from the vegetable and mineral world.
- composition according to the present invention also makes it possible to balance the anterogastric system thanks in particular to the fibers and to the physico-chemical properties of the extracts of selected plants.
- composition according to the present invention therefore makes it possible both to treat gastric ulcers and to prevent them according to the dosages and relative percentages of active compounds prescribed.
- composition according to the invention can easily be obtained from plant materials and therefore it is inexpensive and respectful of the environment.
- cinnamon according to the invention brings many advantages. It admits useful physical properties in the elaboration of the final solution and it also allows to better fix the calcium. It also helps fight the effects of oxidative stress.
- composition according to the invention are numerous, among which mention may be made for horses, under veterinary supervision:
- the process for manufacturing a composition according to the present invention comprises the following various steps.
- Step a/ Plant raw materials containing all the natural extracts of the composition according to the invention are collected. These plant materials can be packaged in different ways.
- the raw materials used in this process are preferably clove heads and/or stems, turmeric roots, ginger roots, thyme leaves, garlic cloves and optionally cinnamon bark.
- the quantity of the various vegetable raw materials is adjusted, for example by the physical measurement of the final solution.
- Step b/ If the plant materials are delivered with a water content greater than 25%, they are dried.
- This step makes it possible to improve the preservation of the plant materials in the case where the following steps of the process are implemented after a significant period of time, generally after between 20 and 45 days.
- the present drying allows to preserve all the properties of the plants and their benefits. Moreover, the more the slow drying gives certain plants a transformation favorable to the concentration of certain active molecules, which are essential for the synergy of the mixture to work.
- Stage c/ in order to improve the transfer of the natural extracts of the plant materials to the solution during the implementation of the following stage d/, the plant materials are ground.
- This grinding stage c/ can be carried out in a hammer mill.
- the particle size of each ground material provides the future formulation with a diffusion rate of active molecules delayed over time, which is important for starting the healing phase.
- the grinding parameters are easily adapted according to the desired consistency of the ground material.
- the plant materials can be in the form of powder or long fibres. They can also be in the form of a substance having the consistency of a puree of vegetable matter.
- Step d/ The plant materials, if necessary, crushed are brought into contact with an aqueous, hydro-alcoholic or alcoholic solution for a period of between 3 and 40 days, at a temperature of between 25° and 35° and a pressure between 1 and 2 bars, so as to obtain natural extracts contained in plant materials.
- This step is generally carried out in a stainless steel tank with stirrer with thermostat in order to control the temperature and optimize it to improve the extraction of the active molecules without modifying them.
- the plant materials are left to macerate for 30 days in demineralized water, at an ambient temperature generally between 15 and 27°C and preferably at 25°C.
- This step can also be carried out in a stirred tank. This saves maceration time.
- Step e/ Once the step of bringing the solution into contact with the plant materials has been completed, the solution is separated from the plant materials and the natural extracts obtained, preferably carried out by filtration, decantation or centrifugation.
- a colloidal solution containing the composition according to the present invention is thus obtained.
- This solution can be used as is.
- the solid matter concentration can be adjusted by adding powder of the same composition or by a step f/ of drying the solution, so as to obtain a powder, preferably produced by freeze-drying, evaporation. This stage f/ is advantageously carried out by evaporation at low temperature.
- the colloidal solution can also be dried to obtain a powder.
- measurement campaigns on the contents of the ingredients of the natural extracts can be carried out on the powder.
- step f / it is possible to provide a step g / of absorption on the powder of the water-soluble active compounds of cinnamon and / or clove and / or turmeric and / or ginger and / or thyme and / or of garlic.
- concentration of the ingredients of the natural extracts can be adjusted as needed by absorbing the water-soluble active elements of clove, turmeric, ginger, thyme, garlic and, if necessary, cinnamon.
- a composition according to the present invention comprises, as natural ingredients, natural extracts of clove, turmeric, ginger, thyme, garlic, optionally cinnamon as well as one or more mineral salts.
- the natural extracts contain respectively at least 10% by weight of eugenol, at least 20% by weight of curcuminoid compounds, at least 5% by weight of sesquiterpene compounds, at least 10% by weight of thymol and at least 12% by weight of carvacrol, at least 3% by weight of sulfur compounds and, where appropriate, at least 40% by weight of cinnamaldehyde.
- a person skilled in the art can easily quantify the content of these molecules by routine chemical analyzes such as, for example, gas chromatography or by spectrometry.
- composition according to the present invention can be produced in different forms depending on the desired application. It can be in the form of a colloidal solution but it can also be with a solution with a suspension mixed with vegetable fibers to obtain a paste.
- It can also be in solid form, preferably in powder form having a particle size mainly between 300 and 600 ⁇ m.
- the powder can be compacted to form a cachet which is easy to administer.
- composition according to the present invention can be supported on an inert porous support.
- inert support is meant here and in the context of the invention, a support which does not interact with the composition according to the invention nor does it modify it.
- An inert porous substrate can be impregnated with a composition according to the present invention in the form of a colloidal solution or a solution without suspension.
- the porous substrate may consist of plant and/or mineral material. It can be an inert fibrous plant substrate, preferably a corn substrate.
- the impregnated porous substrate is in the form of a powder.
- the impregnated porous substrate comprises water-soluble and/or fat-soluble compounds.
- This substrate is not diluted in an aqueous medium but diffuses the water-soluble elements and to a lesser extent the fat-soluble elements.
- composition is advantageous because the assimilation of the latter is done less quickly by the body thanks to the fibers.
- impregnating a support with the composition according to the invention confers an effective temporal inertia on the diffusion of the active elements.
- the process for manufacturing a porous substrate impregnated with a composition according to the invention comprises the following steps: i/ supplying a porous support, preferably consisting of a vegetable and/or mineral material; ii/ impregnation of the porous support with the solution obtained in step e/ of the process described above; iii/ optionally, drying of the impregnated porous substrate according to step ii/.
- the method comprises, before step i/, a washing step i'/ comprising at least one washing cycle of the substrate, preferably in an aqueous solution at a temperature between 5 and 40° C., and preferentially at 90 °C.
- a comparative study was carried out with a group of nine horses to which a composition according to the present invention was administered orally.
- composition according to the invention used comprises an extract of cinnamon, an extract of clove, an extract of turmeric, an extract of ginger, an extract of thyme, an extract of garlic and whose compounds are detailed in Table 1 below.
- the composition is in powder form.
- Table 2 summarizes the various lesions and aspects observed under veterinary supervision, for each of the nine horses in the group, respectively before and after the treatment by ingestion of the composition according to the invention.
- Margo plicatus and pylorus are two areas of the stomach where ulcers are often found.
- the margo plicatus is the area separating the glandular mucosa from the non-glandular mucosa.
- the glandular mucosa makes mucus thus protecting the lower part of the stomach but the upper part (non-glandular mucosa) has no protection against stomach acids. This is why ulcers are often located at the level of the margo plicatus.
- the pylorus is the "sphincter” overlooking the horse's intestines. As this area is most often subjected to stomach acids, many ulcers are found there and the treatment is all the more delicate.
- composition according to the present invention is compatible for administration to competition horses.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids. The invention relates to a composition for gastric treatment, particularly for treating gastric ulcers, comprising the following natural ingredients: - at least 10% by weight of eugenol, at least 1% by weight of ethyl acetate, - at least 2% by weight of curcuminoid compounds, - at least 5% by weight of sesquiterpene, - at least 0.5% by weight of thymol and/or at least 0.5% by weight of carvacrol, - at least 3% by weight of sulphur-containing compounds, - at least 30% by weight of one or more mineral salts, particularly comprising sodium bicarbonate, relative to the total weight of dry matter of the composition.
Description
Description Description
Titre : Title :
COMPOSITION NATURELLE POUR TRAITEMENT GASTRIQUE, NOTAMMENT POUR LE TRAITEMENT D'ULCÈRES GASTRIQUES, PROCÉDÉ DE FABRICATION ASSOCIÉ ET APPLICATION AUX ÉQUIDÉS NATURAL COMPOSITION FOR GASTRIC TREATMENT, IN PARTICULAR FOR THE TREATMENT OF GASTRIC ULCERS, ASSOCIATED MANUFACTURING METHOD AND APPLICATION TO EQUIDAE
Domaine technique Technical area
La présente invention concerne une composition pour le traitement gastrique, en particulier pour le traitement d’ulcères gastriques. The present invention relates to a composition for gastric treatment, in particular for the treatment of gastric ulcers.
Bien que décrite en référence à l’application aux ulcères gastriques d’équidés, la composition selon l’invention peut être mise en œuvre pour le traitement gastrique d’autres animaux, voire d’êtres humains. Although described with reference to the application to gastric ulcers in horses, the composition according to the invention can be used for the gastric treatment of other animals, or even of human beings.
En particulier, elle peut être mises en œuvre pour des animaux dits de rente, de compagnie (chiens, chats), des animaux dits nouveaux animaux de compagnie (acronyme NAC) et à ceux vivants dans les zoos. In particular, it can be implemented for so-called production animals, pets (dogs, cats), so-called new pets (acronym NAC) and those living in zoos.
Elle pourrait aussi être envisagée à terme pour remplacer les molécules dont le principe actif est celui du médicament Oméprazole utilisé à ce jour dans de traitement des ulcères digestifs, du reflux gastro-œsophagien et de ses complications chez l’être humain. It could also be considered in the long term to replace the molecules whose active ingredient is that of the drug Omeprazole used to date in the treatment of digestive ulcers, gastroesophageal reflux and its complications in humans.
Technique antérieure Prior technique
Une étude récente a révélé que 50% des chevaux de loisirs et 90% des chevaux de compétitions sont ou seront touchés par des ulcères gastriques [1], A recent study revealed that 50% of leisure horses and 90% of competition horses are or will be affected by gastric ulcers [1],
Les ulcères gastriques sont des lésions qui apparaissent sur la paroi de l’estomac. Lorsque les ulcères sont en contact avec le suc gastrique, ils peuvent être douloureux. Ces lésions peuvent avoir des influences sur la performance des équidés ainsi que leur humeur. Gastric ulcers are lesions that appear on the stomach wall. When ulcers come in contact with gastric juice, they can be painful. These lesions can have influences on the performance of equines as well as their mood.
Différents produits commerciaux sont connus pour le traitement des ulcères ou pour aider à les prévenir. Various commercial products are known to treat ulcers or to help prevent them.
Parmi ceux-ci, bon nombre contiennent des composés chimiques dont les effets à long terme ne sont pas encore bien identifiés. Of these, many contain chemical compounds whose long-term effects have not yet been well identified.
Le produit désigné sous la dénomination commerciale Gastrogard®, sous forme de pâte est couramment utilisé pour le traitement des ulcères. Ce produit dont la substance active est l’ oméprazole, est certes efficace mais, il présente des effets secondaires comme par exemple un déséquilibre de la flore intestinale, des fragilités osseuses, une mauvaise assimilation des nutriments, un risque important d’effet rebond et donc de récidives encore plus graves. En outre, ce produit est très onéreux.
Les produits commerciaux Ekygard Flash et Ekygard, sont des compositions contenant des bicarbonates, de l'Althaea officinalis, de l'acide hyaluronique et également de l’eugénol et curcumine et des proanthocyanidines et de la cinnamaldéhyde et sont également utilisés pour la prévention des ulcères d’équidés. Ils ne sont pas cependant entièrement naturels et sont également onéreux. The product designated under the trade name Gastrogard®, in the form of a paste, is commonly used for the treatment of ulcers. This product, whose active substance is omeprazole, is certainly effective, but it has side effects such as an imbalance of the intestinal flora, bone fragility, poor assimilation of nutrients, a significant risk of rebound effect and therefore more serious recurrences. In addition, this product is very expensive. The commercial products Ekygard Flash and Ekygard, are compositions containing bicarbonates, Althaea officinalis, hyaluronic acid and also eugenol and curcumin and proanthocyanidins and cinnamaldehyde and are also used for the prevention of ulcers of equines. They are however not entirely natural and are also expensive.
D’autres produits à base de composés naturels sont également commercialisés pour le traitement des ulcères d’équidés. Other products based on natural compounds are also marketed for the treatment of equine ulcers.
On peut citer tout d’abord, le produit Twydil® stomacare qui est une composition à base d’acides gras issus du raffinage, fibres de type glucosamine, trisilicate de magnésium. Ce produit est utilisé pour ses actions curatives et préventives des ulcères. Il agit comme un tampon gastrique et permet d’aider la cicatrisation mais il n’est pas suffisamment actif. Ce produit contient de l’huile de palme et des conservateurs chimiques. L’huile de palme est négativement connue pour toutes les raisons environnementales et les conservateurs chimiques ont à la longue une influence négative sur la santé des mammifères, ainsi que sur l’environnement. First of all, we can mention the product Twydil® stomacare which is a composition based on fatty acids from refining, fibers of the glucosamine type, magnesium trisilicate. This product is used for its curative and preventive actions of ulcers. It acts as a gastric tampon and helps healing but it is not active enough. This product contains palm oil and chemical preservatives. Palm oil is negatively known for all environmental reasons and chemical preservatives have a negative influence on the health of mammals in the long run, as well as the environment.
Des produits entièrement naturels, comme l’argile verte, sont utilisés pour un usage préventif des ulcères. L’argile verte est certes très économique à l’usage mais elle peut provoquer des coliques et agit plutôt comme un pansement gastrique et n’aide donc pas réellement dans la cicatrisation active des ulcères. All-natural products, such as green clay, are used for preventive use of ulcers. Green clay is certainly very economical to use, but it can cause colic and acts more like a gastric bandage and therefore does not really help in the active healing of ulcers.
Le produit commercialisé sous la dénomination Sérénitude est une solution à base de chicorée et de levures de bière qui aide au développement de la flore dans l’estomac, permettant ainsi de prévenir l’apparition des ulcères. Toutefois, ce produit ne permet pas de soigner les ulcères qui sont déjà apparus. En effet, les levures se comportent comme des probiotiques, mais si le terrain (muqueuses) n’est pas équilibré pour que les probiotiques vivent, alors l’ajout de ces prébiotiques ne sera utile que temporairement et cela qu’à condition que des bactéries de type lactobacilles soient présentes en nombre. Autrement dit, son efficacité reste relative. The product marketed under the name Serenitude is a solution based on chicory and brewer's yeast which helps the development of flora in the stomach, thus preventing the appearance of ulcers. However, this product does not cure ulcers that have already appeared. Indeed, yeasts behave like probiotics, but if the ground (mucous membranes) is not balanced for the probiotics to live, then the addition of these prebiotics will only be useful temporarily and that only on condition that bacteria lactobacillus type are present in number. In other words, its effectiveness remains relative.
Les solutions connues ne sont donc pas entièrement satisfaisantes. The known solutions are therefore not entirely satisfactory.
Il existe un besoin pour une composition à base de composés naturels avec des effets secondaires minimisés voire sans aucun effet secondaire, présentant des actions curatives et préventives dans le traitement gastrique, plus particulièrement contre les ulcères notamment chez les équidés.
Le but de la présente invention est de répondre au moins partiellement à ce besoin. There is a need for a composition based on natural compounds with minimized side effects or even without any side effects, exhibiting curative and preventive actions in gastric treatment, more particularly against ulcers, especially in equines. The object of the present invention is to at least partially meet this need.
Exposé de l’invention Disclosure of Invention
Pour ce faire, l’invention a pour obj et une composition pour traitement gastrique, notamment pour traitement des ulcères gastriques, comprenant les ingrédients naturels suivants: To do this, the object of the invention is a composition for gastric treatment, in particular for the treatment of gastric ulcers, comprising the following natural ingredients:
- au moins 10 % en poids d’eugénol, - at least 10% by weight of eugenol,
- au moins 1% en poids d’acétate d’ethyle, - at least 1% by weight of ethyl acetate,
- au moins 2% en poids de composés curcuminoïdes, - at least 2% by weight of curcuminoid compounds,
- au moins 5 % en poids de composés sesquiterpène, - at least 5% by weight of sesquiterpene compounds,
- au moins 0.5 % en poids de thymol et au moins 0.5 % en poids de carvacrol, - at least 0.5% by weight of thymol and at least 0.5% by weight of carvacrol,
- au moins 3% en poids de composés soufrés. - at least 3% by weight of sulfur compounds.
- au moins 30 % en poids d’un ou plusieurs sels minéraux comprenant notamment le bicarbonate de sodium, par rapport au poids total de matière sèche de la composition. - at least 30% by weight of one or more mineral salts comprising in particular sodium bicarbonate, relative to the total weight of dry matter of the composition.
Selon un mode de réalisation avantageux, la composition comprend en outre comme ingrédient naturel, un extrait de cannelle. According to an advantageous embodiment, the composition also comprises, as natural ingredient, a cinnamon extract.
De préférence, l’extrait de cannelle contenant au moins 10% en poids de proanthocyani dines et/ou au moins 10% en poids de cinnamaldéhyde, de préférence de 10 à 20% en poids de cinnamaldéhyde. Preferably, the cinnamon extract containing at least 10% by weight of proanthocyanins and/or at least 10% by weight of cinnamaldehyde, preferably from 10 to 20% by weight of cinnamaldehyde.
Les substances (ingrédients naturels) sont avantageusement extraites, après sélection de leur teneur en composés actifs, dans les végétaux suivants : The substances (natural ingredients) are advantageously extracted, after selection of their content of active compounds, in the following plants:
- girofle (tête), - clove (head),
- curcuma, - turmeric,
- gingembre, - ginger,
- thym, - thyme,
- cannelle, - cinnamon,
- ail, - garlic,
- bicarbonate de sodium. - sodium bicarbonate.
Ainsi, selon une variante de réalisation avantageuse, la composition selon l’invention comprend: Thus, according to an advantageous embodiment variant, the composition according to the invention comprises:
- un extrait de clou de girofle, contenant au moins 10 % en poids d’eugénol et au moins 1% en poids d’acétate d’éthyle, - a clove extract, containing at least 10% by weight of eugenol and at least 1% by weight of ethyl acetate,
- un extrait de curcuma contenant au moins 2% en poids de composés curcuminoïdes,
- un extrait de gingembre contenant au moins 5% en poids de composés sesquiterpène,- a turmeric extract containing at least 2% by weight of curcuminoid compounds, - a ginger extract containing at least 5% by weight of sesquiterpene compounds,
- un extrait de thym contenant au moins 0,5% en poids de thymol et au moins 0,5% en poids de carvacrol, - a thyme extract containing at least 0.5% by weight of thymol and at least 0.5% by weight of carvacrol,
- un extrait d’ail contenant au moins 3% en poids de composés soufrés, - a garlic extract containing at least 3% by weight of sulfur compounds,
- au moins 30% en poids de bicarbonate de sodium, par rapport au poids total de matière sèche de la composition. - at least 30% by weight of sodium bicarbonate, relative to the total weight of dry matter of the composition.
La composition peut être une solution colloïdale ou sous forme solide, de préférence sous forme de poudre, le cas échéant compactée sous la forme de cachet(s). The composition may be a colloidal solution or in solid form, preferably in powder form, if necessary compacted in the form of cachet(s).
La composition selon la présente invention, à base d’ingrédients naturels ou d’origine naturelle contribue à la cicatrisation des ulcères qui peuvent être de grade 1 à 3 sur une échelle de 4 ou 5. En effet, la composition selon la présente invention présente des propriétés cicatrisantes, antiinflammatoire, équilibrantes de la flore et une normalisation du pH. Cet effet est obtenu par la synergie des composés utilisés dont les extractions proviennent du monde végétal et minéral. The composition according to the present invention, based on natural ingredients or of natural origin contributes to the healing of ulcers which can be grade 1 to 3 on a scale of 4 or 5. Indeed, the composition according to the present invention has healing properties, anti-inflammatory, balancing the flora and normalizing the pH. This effect is obtained by the synergy of the compounds used whose extractions come from the vegetable and mineral world.
La composition selon la présente invention permet également d’équilibrer le système antéro- gastrique grâce notamment aux fibres et aux propriétés physico-chimiques des extraits de plantes sélectionnées. The composition according to the present invention also makes it possible to balance the anterogastric system thanks in particular to the fibers and to the physico-chemical properties of the extracts of selected plants.
La composition selon la présente invention permet donc à la fois de traiter les ulcères gastriques et de les prévenir selon les dosages et pourcentages relatifs de composés actifs prescrits. The composition according to the present invention therefore makes it possible both to treat gastric ulcers and to prevent them according to the dosages and relative percentages of active compounds prescribed.
De plus, une composition selon l’invention peut être obtenue aisément à partir de matières végétales et donc elle est peu onéreuse et respectueuse de l’environnement. In addition, a composition according to the invention can easily be obtained from plant materials and therefore it is inexpensive and respectful of the environment.
L’ajout de la cannelle selon l’invention apporte de nombreux avantages. Elle admet des propriétés physiques utiles dans l’élaboration de la solution définitive et elle permet également de mieux fixer le calcium. Elle permet également de lutter contre les effets du stress oxydatif. The addition of cinnamon according to the invention brings many advantages. It admits useful physical properties in the elaboration of the final solution and it also allows to better fix the calcium. It also helps fight the effects of oxidative stress.
Les avantages de la composition selon l’invention sont nombreux parmi lesquels on peut citer pour les équidés, sous contrôle vétérinaire : The advantages of the composition according to the invention are numerous, among which mention may be made for horses, under veterinary supervision:
- un maintien du bien-être gastrique des équidés ; aucun effet secondaire induit ; - maintenance of the gastric well-being of equines; no induced side effects;
- un maintien de l’équilibre de la flore intestinale ; l’absence de fragilisation des équidés ;
l’absence de perturbation de l’assimilation de certains nutriments ; - maintenance of the balance of the intestinal flora; the absence of weakening of equidae; the absence of disruption of the assimilation of certain nutrients;
- un produit non dopant validé par un certificat sous la référence LCH N°D20127_l ;- a non-doping product validated by a certificate under the reference LCH N°D20127_l;
- un produit plus économique que les produits commerciaux existants ; un gain d’énergie pour les équidés après traitement ; - a more economical product than existing commercial products; an energy gain for equines after treatment;
- une reprise d’état et des performances améliorées. - improved state recovery and performance.
Description détaillée detailed description
PROCEDE PROCESS
Le procédé de fabrication d’une composition selon la présente invention comprend les différentes étapes suivantes. The process for manufacturing a composition according to the present invention comprises the following various steps.
Etape a/ : Des matières premières végétales contenant l’ensemble des extraits naturels de la composition selon l’invention sont collectées. Ces matières végétales peuvent être conditionnées de différentes manières. Les matières premières utilisées dans ce procédé sont de préférence les têtes et/ou tiges de clous de girofle, les racines de curcuma, les racines de gingembre, les feuilles de thym, des gousses d’ail et optionnellement des écorces de cannelle. Step a/: Plant raw materials containing all the natural extracts of the composition according to the invention are collected. These plant materials can be packaged in different ways. The raw materials used in this process are preferably clove heads and/or stems, turmeric roots, ginger roots, thyme leaves, garlic cloves and optionally cinnamon bark.
Suivant la composition finale souhaitée, la quantité des différentes matières premières végétales est ajustée, par exemple par la mesure physique de la solution finale. Depending on the desired final composition, the quantity of the various vegetable raw materials is adjusted, for example by the physical measurement of the final solution.
Etape b/ : Si les matières végétales sont livrées avec une teneur en eau supérieure à 25%, elles sont séchées. Step b/: If the plant materials are delivered with a water content greater than 25%, they are dried.
Cette étape permet d’améliorer la conservation des matières végétales dans le cas où les étapes suivantes du procédé sont mises en œuvre après un laps de temps important, généralement après entre 20 et 45 jours. Le séchage présente permet de préserver l’ensemble des propriétés des plantes et leurs bienfaits. De, plus le séchage lent procure à certains végétaux une transformation favorable à la concentration de certaines molécules actives, indispensables pour que la synergie du mélange fonctionne. This step makes it possible to improve the preservation of the plant materials in the case where the following steps of the process are implemented after a significant period of time, generally after between 20 and 45 days. The present drying allows to preserve all the properties of the plants and their benefits. Moreover, the more the slow drying gives certain plants a transformation favorable to the concentration of certain active molecules, which are essential for the synergy of the mixture to work.
Etape c/ : afin d’améliorer le transfert des extraits naturels des matières végétales vers la solution lors de la mise en œuvre de l’étape suivante d/, les matières végétales sont broyées. Cette étape c/ de broyage peut être réalisée dans un broyeur à marteau. La granulométrie de chaque broyât procure à la future formulation un taux de diffusion des molécules actives différées dans le temps, ce qui est important pour démarrer la phase de cicatrisation. Bien évidemment, les paramètres de broyage sont aisément adaptés suivant la consistance désirée de la matière broyée.
Ainsi, après l’étape de broyage les matières végétales peuvent être sous forme de poudre ou de longues fibres. Elles peuvent être également sous forme d’une substance ayant la consistance d’une purée de matières végétales. Stage c/: in order to improve the transfer of the natural extracts of the plant materials to the solution during the implementation of the following stage d/, the plant materials are ground. This grinding stage c/ can be carried out in a hammer mill. The particle size of each ground material provides the future formulation with a diffusion rate of active molecules delayed over time, which is important for starting the healing phase. Of course, the grinding parameters are easily adapted according to the desired consistency of the ground material. Thus, after the grinding step, the plant materials can be in the form of powder or long fibres. They can also be in the form of a substance having the consistency of a puree of vegetable matter.
Etape d/ : Les matières végétales, le cas échéant, broyées sont mises en contact avec une solution aqueuse, ou hydro-alcoolique ou alcoolique pendant une durée comprise entre 3 et 40 jours, à une température comprise entre 25° et 35° et une pression comprise entre 1 et 2 bars, de sorte à obtenir des extraits naturels contenus dans les matières végétales. Cette étape est généralement réalisée dans une cuve inox avec agitateur avec thermostat afin de contrôler la température et l’optimiser pour améliorer l’extraction des molécules actives sans les modifier. Step d/: The plant materials, if necessary, crushed are brought into contact with an aqueous, hydro-alcoholic or alcoholic solution for a period of between 3 and 40 days, at a temperature of between 25° and 35° and a pressure between 1 and 2 bars, so as to obtain natural extracts contained in plant materials. This step is generally carried out in a stainless steel tank with stirrer with thermostat in order to control the temperature and optimize it to improve the extraction of the active molecules without modifying them.
De préférence, on laisse macérer les matières végétales pendant 30 jours dans de l’eau déminéralisée, à une température ambiante généralement entre 15 et 27°C et préférentiellement à 25°C. Preferably, the plant materials are left to macerate for 30 days in demineralized water, at an ambient temperature generally between 15 and 27°C and preferably at 25°C.
Cette étape peut être également réalisée dans une cuve agitée. Cela permet un gain de temps de macération. This step can also be carried out in a stirred tank. This saves maceration time.
Etape e/ : Une fois l’étape de mise en contact de la solution et des matières végétales achevée, la solution est séparée des matières végétales et des extraits naturels obtenus, de préférence réalisée par filtration, décantation ou centrifugation. Step e/: Once the step of bringing the solution into contact with the plant materials has been completed, the solution is separated from the plant materials and the natural extracts obtained, preferably carried out by filtration, decantation or centrifugation.
Une solution colloïdale contenant la composition selon la présente invention est ainsi obtenue. Cette solution est utilisable telle quelle. La concentration en matière solide peut être ajustée par ajout de poudre d’une même composition ou par une étape f/ de séchage de la solution, de sorte à obtenir une poudre, de préférence réalisée par une lyophilisation, évaporation. Cette étape f/ est faite avantageusement par évaporation à basse température. La solution colloïdale peut être également séchée afin d’obtenir une poudre. A colloidal solution containing the composition according to the present invention is thus obtained. This solution can be used as is. The solid matter concentration can be adjusted by adding powder of the same composition or by a step f/ of drying the solution, so as to obtain a powder, preferably produced by freeze-drying, evaporation. This stage f/ is advantageously carried out by evaporation at low temperature. The colloidal solution can also be dried to obtain a powder.
Après l’étape f/ de séchage, des campagnes de mesures sur les teneurs des ingrédients des extraits naturels peuvent être réalisées sur la poudre. After the drying step f/, measurement campaigns on the contents of the ingredients of the natural extracts can be carried out on the powder.
Il est également possible de réaliser les mesures sur la solution colloïdale obtenue à l’étape e/. It is also possible to carry out the measurements on the colloidal solution obtained in step e/.
Après l’étape f/, on peut prévoir une étape g/ d’absorption sur la poudre des composés actifs hydrosolubles de cannelle et/ou de clou girofle et/ou de curcuma et/ou de gingembre et/ou de thym et/ou d’ail.
La concentration des ingrédients des extraits naturels peut être ajustée selon le besoin par absorption des éléments actifs hydrosolubles de clou de girofle, de curcuma, de gingembre, de thym, d’ail et le cas échéant de cannelle. After step f /, it is possible to provide a step g / of absorption on the powder of the water-soluble active compounds of cinnamon and / or clove and / or turmeric and / or ginger and / or thyme and / or of garlic. The concentration of the ingredients of the natural extracts can be adjusted as needed by absorbing the water-soluble active elements of clove, turmeric, ginger, thyme, garlic and, if necessary, cinnamon.
COMPOSITION COMPOSITION
Une composition selon la présente invention comprend en tant qu’ingrédients naturels, des extrait naturels de clou de girofle, de curcuma, de gingembre, de thym, d’ail, optionnellement de cannelle ainsi qu’un ou plusieurs sels minéraux. A composition according to the present invention comprises, as natural ingredients, natural extracts of clove, turmeric, ginger, thyme, garlic, optionally cinnamon as well as one or more mineral salts.
Les extraits naturels contiennent respectivement au moins 10 % en poids d’eugénol, au moins 20 % en poids de composés curcuminoïdes, au moins 5% en poids de composés sesquiterpène, au moins 10% en poids de thymol et au moins 12 % en poids de carvacrol, au moins 3% en poids de composés soufrés et le cas échéant au moins 40 % en poids cinnamaldéhyde. The natural extracts contain respectively at least 10% by weight of eugenol, at least 20% by weight of curcuminoid compounds, at least 5% by weight of sesquiterpene compounds, at least 10% by weight of thymol and at least 12% by weight of carvacrol, at least 3% by weight of sulfur compounds and, where appropriate, at least 40% by weight of cinnamaldehyde.
L’homme du métier peut aisément quantifier la teneur en ces molécules par des analyses chimiques de routine comme par exemple la chromatographie en phase gazeuse ou par spectrométrie. A person skilled in the art can easily quantify the content of these molecules by routine chemical analyzes such as, for example, gas chromatography or by spectrometry.
La composition selon la présente invention peut être réalisée sous différentes formes suivant l’application désirée. Elle peut être sous forme de solution colloïdale mais elle peut être aussi avec une solution avec suspension mélangée à des fibres végétales pour obtenir une pâte.The composition according to the present invention can be produced in different forms depending on the desired application. It can be in the form of a colloidal solution but it can also be with a solution with a suspension mixed with vegetable fibers to obtain a paste.
Elle peut être également sous forme solide, de préférence sous forme de poudre présentant une granulométrie principalement comprise entre 300 et 600 pm. It can also be in solid form, preferably in powder form having a particle size mainly between 300 and 600 μm.
La poudre peut être compactée afin de former un cachet qui est facile à administrer. The powder can be compacted to form a cachet which is easy to administer.
COMPOSITION SUPPORTEE SUPPORTED COMPOSITION
La composition selon la présente invention peut être supportée sur un support poreux inerte. Par « support inerte », on entend ici et dans le cadre de l’invention, un support qui n’interagit pas avec la composition selon l’invention ni ne la modifie. The composition according to the present invention can be supported on an inert porous support. By “inert support” is meant here and in the context of the invention, a support which does not interact with the composition according to the invention nor does it modify it.
Un substrat poreux inerte peut être imprégné d’une composition selon la présente invention sous la forme d’une solution colloïdale ou d’une solution sans suspension. Le substrat poreux peut être constitué d’une matière végétale et/ou minérale. Il peut s’agir d’un substrat végétal fibreux inerte, de préférence un substrat en maïs. An inert porous substrate can be impregnated with a composition according to the present invention in the form of a colloidal solution or a solution without suspension. The porous substrate may consist of plant and/or mineral material. It can be an inert fibrous plant substrate, preferably a corn substrate.
Avantageusement, le substrat poreux imprégné est sous forme d’une poudre.
Le substrat poreux imprégné comprend des composés hydrosolubles et/ou liposolubles.Advantageously, the impregnated porous substrate is in the form of a powder. The impregnated porous substrate comprises water-soluble and/or fat-soluble compounds.
Ce substrat ne se dilue pas dans un milieu aqueux mais diffuse les éléments hydrosolubles et dans une moindre mesure les éléments liposolubles. This substrate is not diluted in an aqueous medium but diffuses the water-soluble elements and to a lesser extent the fat-soluble elements.
Le fait de supporter la composition est avantageux car l’assimilation de cette dernière se fait moins rapidement par l’organisme grâce aux fibres. The fact of supporting the composition is advantageous because the assimilation of the latter is done less quickly by the body thanks to the fibers.
Ainsi, imprégner un support avec la composition selon l’invention confère une inertie temporelle effective sur la diffusion des éléments actifs. Thus, impregnating a support with the composition according to the invention confers an effective temporal inertia on the diffusion of the active elements.
Ainsi, le de fabrication d’un substrat poreux imprégné avec une composition selon l’invention comprend les étapes suivantes : i/ fourniture d’un support poreux, de préférence constitué d’une matière végétale et/ou minérale ; ii/ imprégnation du support poreux par la solution obtenue à l’étape e/ du procédé décrit précédemment; iii/ optionnellement, séchage du substrat poreux imprégné selon l’étape ii/. Thus, the process for manufacturing a porous substrate impregnated with a composition according to the invention comprises the following steps: i/ supplying a porous support, preferably consisting of a vegetable and/or mineral material; ii/ impregnation of the porous support with the solution obtained in step e/ of the process described above; iii/ optionally, drying of the impregnated porous substrate according to step ii/.
Avantageusement, le procédé comprend avant l’étape i/, une étape i’/ de lavage comprenant au moins un cycle de lavage du substrat, de préférence dans une solution aqueuse à une température comprise entre 5 et 40°C, et préférentiellement à 90°C. Advantageously, the method comprises, before step i/, a washing step i'/ comprising at least one washing cycle of the substrate, preferably in an aqueous solution at a temperature between 5 and 40° C., and preferentially at 90 °C.
EXEMPLE EXAMPLE
Une étude comparative a été réalisée avec un groupe de neuf chevaux auquel une composition selon la présente invention a été administrée par voie buccale. A comparative study was carried out with a group of nine horses to which a composition according to the present invention was administered orally.
La composition selon l’invention utilisée comprend un extrait de cannelle, un extrait de clou de girofle, un extrait de curcuma, un extrait de gingembre, un extrait de thym, un extrait d’ail et dont les composés sont détaillés dans le Tableau 1 ci-dessous. The composition according to the invention used comprises an extract of cinnamon, an extract of clove, an extract of turmeric, an extract of ginger, an extract of thyme, an extract of garlic and whose compounds are detailed in Table 1 below.
La composition est sous forme de poudre. The composition is in powder form.
Le protocole a consisté à administrer par voie buccale une dosette de poudre de 15g par jour de ladite composition pendant au moins un mois.
[Tableau 1]
The protocol consisted in administering orally a 15 g powder dosette per day of said composition for at least one month. [Table 1]
On a résumé dans le Tableau 2 ci-dessous, les différentes lésions et aspects observés sous contrôle vétérinaire, pour chacun des neuf chevaux du groupe, respectivement avant et après le traitement par ingestion de la composition selon l’invention. Table 2 below summarizes the various lesions and aspects observed under veterinary supervision, for each of the nine horses in the group, respectively before and after the treatment by ingestion of the composition according to the invention.
Les clichés à partir desquels les observations/constats ont été faits par gastroscopie.
The pictures from which the observations/findings were made by gastroscopy.
[Tableau 2][Table 2]
[Tablean 2]
[Table 2]
NC = Inconnu NC = Unknown
* Margo plicatus et pylore sont deux zones de l’estomac ou l’on retrouve souvent des ulcères. La margo plicatus correspond à la zone séparant la muqueuse glandulaire de la muqueuse non glandulaire. La muqueuse glandulaire fabrique du mucus protégeant ainsi la partie inférieure de l’estomac mais la partie supérieur (muqueuse non glandulaire) ne dispose d’aucune protection contre les acides de l’estomac. C’est pour cela que souvent les ulcères se situent au niveau de la margo plicatus Le pylore quant à lui est la « sphincter » donnant sur les intestins du cheval. Comme cette zone est la plus souvent soumise aux acides de l’estomac, de nombreux ulcères s’y trouvent et le soin et d’autant plus délicat. * Margo plicatus and pylorus are two areas of the stomach where ulcers are often found. The margo plicatus is the area separating the glandular mucosa from the non-glandular mucosa. The glandular mucosa makes mucus thus protecting the lower part of the stomach but the upper part (non-glandular mucosa) has no protection against stomach acids. This is why ulcers are often located at the level of the margo plicatus. The pylorus is the "sphincter" overlooking the horse's intestines. As this area is most often subjected to stomach acids, many ulcers are found there and the treatment is all the more delicate.
** l’hyperkératose et un phénomène inflammatoire des muqueuses gastriques. ** hyperkeratosis and an inflammatory phenomenon of the gastric mucosa.
Par « prise d’état », on entend ici et dans le cadre de l’invention une prise de poids.
By "status" is meant here and in the context of the invention a weight gain.
Il ressort de l’étude et du tableau 2 que l’administration d’une composition selon la présente invention permet une cicatrisation des équidés étudiés, avec un taux d’efficacité de 70%, c’est-à-dire que sept équidés sur 10 présentaient une bonne cicatrisation. It emerges from the study and from Table 2 that the administration of a composition according to the present invention allows healing of the horses studied, with an efficiency rate of 70%, that is to say that seven horses out of 10 showed good healing.
Des échantillons d’urine et de sang des chevaux objets de l’étude ont été analysés, afin de vérifier si des substances prohibées pour des courses hippiques y sont présentes. L’ensemble des échantillons a été déclaré négatif. Par conséquent, la composition selon l’invention est non-dopante. Urine and blood samples from the horses involved in the study were analyzed to check whether substances prohibited for horse racing are present. All the samples were declared negative. Consequently, the composition according to the invention is non-doping.
Ainsi, la composition selon la présente invention est compatible pour une administration à des équidés de compétition. Liste des références citées Thus, the composition according to the present invention is compatible for administration to competition horses. List of cited references
[1] : Maud Henry, « Accompagnement de l’éleveur équin à l’officine: prévention et traitement de l’ulcère gastrique du cheval ». Sciences pharmaceutiques. 2017. ffdumas- 01556732ff
[1]: Maud Henry, “Accompaniment of the horse breeder at the pharmacy: prevention and treatment of gastric ulcer in horses”. Pharmaceutical sciences. 2017. ffdumas-01556732ff
Claims
1. Composition pour traitement gastrique, notamment pour le traitement d’ulcères gastriques comprenant les ingrédients naturels suivants: 1. Composition for gastric treatment, in particular for the treatment of gastric ulcers comprising the following natural ingredients:
- au moins 10% en poids d’eugénol , - at least 10% by weight of eugenol,
- au moins 1% en poids d’acétate d’éthyle, - at least 1% by weight of ethyl acetate,
- au moins 2% en poids de composés curcuminoïdes, - at least 2% by weight of curcuminoid compounds,
- au moins 5% en poids de composés sesquiterpène, - at least 5% by weight of sesquiterpene compounds,
- au moins 0,5% en poids de thymol et/ou au moins 0,5 % en poids de carvacrol,- at least 0.5% by weight of thymol and/or at least 0.5% by weight of carvacrol,
- au moins 3% en poids de composés soufrés, - at least 3% by weight of sulfur compounds,
- au moins 30% en poids d’un ou plusieurs sels minéraux, comprenant notamment le bicarbonate de sodium, par rapport au poids total de matière sèche de la composition. - at least 30% by weight of one or more mineral salts, including in particular sodium bicarbonate, relative to the total weight of dry matter of the composition.
2. Composition selon la revendication 1, comprenant en outre comme ingrédient naturel, un extrait de cannelle. 2. Composition according to claim 1, further comprising as natural ingredient, a cinnamon extract.
3. Composition selon la revendication 2, l’extrait de cannelle contenant au moins 10% en poids de proanthocyanidines et/ou au moins 10% en poids de cinnamaldéhyde, de préférence de 10 à 20% en poids de cinnamaldéhyde. 3. Composition according to claim 2, the cinnamon extract containing at least 10% by weight of proanthocyanidins and/or at least 10% by weight of cinnamaldehyde, preferably from 10 to 20% by weight of cinnamaldehyde.
4. Composition selon l’une des revendications 1 ou 2, comprenant : 4. Composition according to one of claims 1 or 2, comprising:
- un extrait de clou de girofle, contenant au moins 10 % en poids d’eugénol et au moins 1% en poids d’acétate d’éthyle, - a clove extract, containing at least 10% by weight of eugenol and at least 1% by weight of ethyl acetate,
- un extrait de curcuma contenant au moins 2% en poids de composés curcuminoïdes,- a turmeric extract containing at least 2% by weight of curcuminoid compounds,
- un extrait de gingembre contenant au moins 5% en poids de composés sesquiterpène,- a ginger extract containing at least 5% by weight of sesquiterpene compounds,
- un extrait de thym contenant au moins 0,5% en poids de thymol et au moins 0,5% en poids de carvacrol, - a thyme extract containing at least 0.5% by weight of thymol and at least 0.5% by weight of carvacrol,
- un extrait d’ail contenant au moins 3% en poids de composés soufrés, - a garlic extract containing at least 3% by weight of sulfur compounds,
- au moins 30% en poids de bicarbonate de sodium, par rapport au poids total de matière sèche de la composition. - at least 30% by weight of sodium bicarbonate, relative to the total weight of dry matter of the composition.
5. Composition selon l’une quelconque des revendications précédentes, la composition étant une solution colloïdale. 5. Composition according to any one of the preceding claims, the composition being a colloidal solution.
6. Composition selon l’une quelconque des revendications 1 à 4, la composition étant sous forme solide, de préférence sous forme de poudre, le cas échéant compactée sous la forme de cachet(s).
6. Composition according to any one of claims 1 to 4, the composition being in solid form, preferably in powder form, if necessary compacted in the form of cachet(s).
7. Substrat poreux imprégné par une composition selon la revendication 6. 7. Porous substrate impregnated with a composition according to claim 6.
8. Substrat selon la revendication 7, le substrat étant constitué d’une matière végétale et/ou minérale. 8. Substrate according to claim 7, the substrate consisting of a vegetable and/or mineral material.
9. Substrat selon la revendication 7, le substrat étant un substrat végétal fibreux inerte, de préférence un substrat en maïs. 9. Substrate according to claim 7, the substrate being an inert fibrous plant substrate, preferably a maize substrate.
10. Procédé de fabrication d’une composition selon l’une quelconque des revendications 1 à 6, comprenant les étapes suivantes : a/ fourniture de matières premières végétales comprenant: 10. A method of manufacturing a composition according to any one of claims 1 to 6, comprising the following steps: a / supply of plant raw materials comprising:
- du girofle, de préférence des têtes et/ou de tiges de clous de girofle, - cloves, preferably heads and/or stems of cloves,
- du curcuma, de préférence des racines de curcuma, - turmeric, preferably turmeric roots,
- du gingembre, de préférence des racines de gingembre, - ginger, preferably ginger roots,
- du thym, de préférence des feuilles de thym, - thyme, preferably thyme leaves,
- de l’ail, de préférence des gousses d’ail; b/ optionnellement, si les matières végétales sont livrées avec une teneur en eau supérieure à 25%, séchage des matières premières végétales, de sorte à réduire la teneur en eau, c/ optionnellement, broyage des matières végétales, de sorte à obtenir une poudre ou une substance présentant la consistance d'une purée desdites matières premières végétales; d/ mise en contact des matières premières végétales avec une solution aqueuse ou hydroalcoolique ou alcoolique pendant une durée comprise entre 3 et 40 jours , à une température comprise entre 25° et 35° et une pression comprise entre 1 et 2 bars, de sorte à obtenir des extraits naturels des matières végétales, e/ séparation de la solution et des extraits naturels obtenus, de préférence réalisée par filtration, décantation ou centrifugation. - garlic, preferably garlic cloves; b/ optionally, if the plant materials are delivered with a water content greater than 25%, drying of the plant raw materials, so as to reduce the water content, c/ optionally, grinding the plant materials, so as to obtain a powder or a substance having the consistency of a puree of said vegetable raw materials; d/ bringing plant raw materials into contact with an aqueous or hydroalcoholic or alcoholic solution for a period of between 3 and 40 days, at a temperature of between 25° and 35° and a pressure of between 1 and 2 bar, so as to obtaining natural extracts of plant materials, e/ separation of the solution and of the natural extracts obtained, preferably carried out by filtration, decantation or centrifugation.
11. Procédé de fabrication selon la revendication 10, l’ étape a / comprenant la fourniture de cannelle, de préférence des écorces de cannelle. 11. A method of manufacture according to claim 10, step a/ comprising providing cinnamon, preferably cinnamon bark.
12. Procédé de fabrication selon la revendication 10 ou 11, comprenant, après l’étape e/, une étape f/ de séchage de la solution, de sorte à obtenir une poudre, de préférence réalisée par une lyophilisation, évaporation. 12. Manufacturing process according to claim 10 or 11, comprising, after step e/, a step f/ of drying the solution, so as to obtain a powder, preferably produced by freeze-drying, evaporation.
13. Procédé de fabrication selon la revendication 12, comprenant, après l’étape f/, une étape g/ d’absorption sur la poudre des composés actifs hydrosolubles de cannelle et/ou de clou girofle et/ou de curcuma et/ou de gingembre et/ou de thym et/ou d’ail.
15 13. Manufacturing process according to claim 12, comprising, after step f/, a step g/ of absorption onto the powder of the water-soluble active compounds of cinnamon and/or clove and/or turmeric and/or ginger and/or thyme and/or garlic. 15
14. Procédé de fabrication d’un substrat poreux imprégné selon l’une quelconque des revendications 7 à 9 comprenant les étapes suivantes : i/ fourniture d’un support poreux, de préférence constitué d’une matière végétale et/ou minérale ; ii/ imprégnation du support poreux par la solution obtenue à l’ étape e/ du procédé selon l’une des revendications 10 à 13; iii/ optionnellement, séchage du substrat poreux imprégné selon l’étape ii/. 14. Process for manufacturing an impregnated porous substrate according to any one of claims 7 to 9 comprising the following steps: i/ providing a porous support, preferably consisting of a plant and/or mineral material; ii/ impregnation of the porous support with the solution obtained in step e/ of the process according to one of claims 10 to 13; iii/ optionally, drying of the impregnated porous substrate according to step ii/.
15. Procédé de fabrication selon revendication 14, comprenant, avant l’étape i/, une étape i’/ de lavage comprenant au moins un cycle de lavage du substrat, de préférence dans une solution aqueuse à une température comprise entre 5 et 40°C, et préférentiellement à 90°C.
15. Manufacturing process according to claim 14, comprising, before step i/, a washing step i'/ comprising at least one cycle of washing the substrate, preferably in an aqueous solution at a temperature between 5 and 40° C, and preferably at 90°C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FRFR2011220 | 2020-11-02 | ||
| FR2011220A FR3115679B1 (en) | 2020-11-02 | 2020-11-02 | Natural composition for gastric treatment, in particular for the treatment of gastric ulcers, associated manufacturing process and application to equines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022090561A1 true WO2022090561A1 (en) | 2022-05-05 |
Family
ID=74553957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2021/080315 WO2022090561A1 (en) | 2020-11-02 | 2021-11-02 | Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR3115679B1 (en) |
| WO (1) | WO2022090561A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099726A1 (en) * | 2004-04-15 | 2005-10-27 | Universidade Estadual De Campinas - Unicamp | ANTI-ULCEROGENIC ACTIVITIES OF SESQUITERPENS AND POLYACETYLENES OF A DICHLOROMETHANIC EXTRACT OF Bidens alba L. |
| FR2884828A1 (en) * | 2005-04-26 | 2006-10-27 | Patrice Chauvin | Dietetic/pharmaceutical composition to fight against mental and physical tiredness, comprises cola nut, ginger, garlic, sorrel of guinea/bissap, clove, nettle, curcuma, yohimbe and salicorne plants |
| WO2012056141A2 (en) * | 2010-10-29 | 2012-05-03 | Bernard Mompon | Method for producing articles of plant origin impregnated with a liquid plant substance |
| CN101386613B (en) * | 2007-09-11 | 2012-05-23 | 兰州大学 | Technique for extracting isoflavones materials from red clover |
| US20170325463A1 (en) * | 2015-11-16 | 2017-11-16 | Joseph Hoeflich | Trichome and Pistil Maturing Formulation |
| CN106620474B (en) * | 2016-12-28 | 2020-03-24 | 王国栋 | Stomach-nourishing health-care medicine and preparation method thereof |
-
2020
- 2020-11-02 FR FR2011220A patent/FR3115679B1/en active Active
-
2021
- 2021-11-02 WO PCT/EP2021/080315 patent/WO2022090561A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099726A1 (en) * | 2004-04-15 | 2005-10-27 | Universidade Estadual De Campinas - Unicamp | ANTI-ULCEROGENIC ACTIVITIES OF SESQUITERPENS AND POLYACETYLENES OF A DICHLOROMETHANIC EXTRACT OF Bidens alba L. |
| FR2884828A1 (en) * | 2005-04-26 | 2006-10-27 | Patrice Chauvin | Dietetic/pharmaceutical composition to fight against mental and physical tiredness, comprises cola nut, ginger, garlic, sorrel of guinea/bissap, clove, nettle, curcuma, yohimbe and salicorne plants |
| CN101386613B (en) * | 2007-09-11 | 2012-05-23 | 兰州大学 | Technique for extracting isoflavones materials from red clover |
| WO2012056141A2 (en) * | 2010-10-29 | 2012-05-03 | Bernard Mompon | Method for producing articles of plant origin impregnated with a liquid plant substance |
| US20170325463A1 (en) * | 2015-11-16 | 2017-11-16 | Joseph Hoeflich | Trichome and Pistil Maturing Formulation |
| CN106620474B (en) * | 2016-12-28 | 2020-03-24 | 王国栋 | Stomach-nourishing health-care medicine and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| EMAN MOHAMED ET AL: "Evaluation of Antiulcer Activity of Ginger, Clove and Castor Oils Against Aspirin Induced Gastric Ulcers in Rats", WORLD APPLIED SCIENCES JOURNAL, 1 January 2014 (2014-01-01), pages 815 - 824, XP055817025, Retrieved from the Internet <URL:http://www.idosi.org/wasj/wasj29(7)14/1.pdf> [retrieved on 20210623], DOI: 10.5829/idosi.wasj.2014.29.07.13963 * |
| IRISDALVA S OLIVEIRA ET AL: "Gastroprotective activity of carvacrol on experimentally induced gastric lesions in rodents", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 385, no. 9, 28 June 2012 (2012-06-28), pages 899 - 908, XP035098701, ISSN: 1432-1912, DOI: 10.1007/S00210-012-0771-X * |
| KUMAR SUDIP ET AL: "Antiulcer agents: A pharmacological update of the past ten years", ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH, 1 June 2019 (2019-06-01), pages 37 - 41, XP055817128, Retrieved from the Internet <URL:https://www.researchgate.net/publication/335378399_ANTIULCER_AGENTS_A_PHARMACOLOGICAL_UPDATE_OF_THE_PAST_TEN_YEARS/link/5d60ff47299bf1f70b08feb4/download> [retrieved on 20210623], DOI: 10.22159/ajpcr.2019.v12i8.34175 * |
| RIBEIRO ANA ROSELI S ET AL: "Gastroprotective effects of thymol on acute and chronic ulcers in rats: The role of prostaglandins, ATP-sensitive K+channels, and gastric mucus secretion", CHEMICO-BIOLOGICAL INTERACTIONS, ELSEVIER SCIENCE IRLAND, IR, vol. 244, 13 December 2015 (2015-12-13), pages 121 - 128, XP029382796, ISSN: 0009-2797, DOI: 10.1016/J.CBI.2015.12.004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3115679B1 (en) | 2023-10-27 |
| FR3115679A1 (en) | 2022-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2219477B1 (en) | Composition for regulating lipid metabolism | |
| EP0022046B1 (en) | Drug composition based on plants and process for its preparation | |
| FR3054443A1 (en) | HIGHLY CONCENTRATED SAFRANAL PLANT EXTRACT, PROCESS FOR OBTAINING AND USES | |
| CA3002753A1 (en) | Specific nutritional or therapeutic agent including a mixture of grape and blueberry | |
| Ano et al. | Composition biochimique et phytochimique des tourteaux des fruits du safoutier (Dacryodes edulis) de Côte d’Ivoire | |
| FR2888235A1 (en) | Extraction of sulforaphane from broccoli seed extract containing glucoraphanin, comprises hydrolyzing the extract, and extracting carbohydrates and lipids in hydrolyzed extract, by water containing sulforaphane | |
| FR3080989A1 (en) | LIQUID COMPOSITION COMPRISING AN EXTRACT OF CASSIS LEAVES AND CONCENTRATED APPLE JUICE | |
| FR2833813A1 (en) | Dietary supplement for animals, useful for preventing or treating coccidiosis, comprises a eucalyptus extract | |
| Salman et al. | Blood glucose-lowering effect of Telfairia Occidentalis: A preliminary study on the underlying mechanism and responses. | |
| Haddouchi et al. | Phytochemical screening, antioxidant activities and hemolytic power of four Saharan plants from Algeria | |
| WO2022090561A1 (en) | Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids | |
| N’draman-Donou et al. | Caractérisation et évaluation in vitro de l’effet antifalcimiant des graines de Cajanus cajan (Fabacées) sur les drépanocytes à Abidjan-Côte d’Ivoire | |
| FR2905827A1 (en) | Antioxidant additive, useful to incorporate into food, food complement/food supplement for animal, preferably ruminant, comprises herbal extract e.g. extracts of artichoke, rosemary, tagete, turmeric, citrus fruits, garlic and nettle | |
| KR101478196B1 (en) | Composition for the prevention of foods from oxidation and for retarding the onset of diabetes comprsing of the extract of Cudrania tricuspidata as a main component | |
| Bettaieb Rebey et al. | Etude de la composition chimique et de l’activité antioxydante des différents extraits de la Lavande dentée (Lavandula dentata) | |
| WO2019038100A1 (en) | Combination product for relieving the symptoms associated with upper respiratory tract infections | |
| FR2936711A1 (en) | Composition, useful as a dietary supplement for e.g. the prevention and/or treatment of hypercholesterolemia, comprises a combination of hypolipidemic agents including at least one dry extract of artichoke leaves and red yeast rice | |
| WO2022180233A1 (en) | Repellent natural composition | |
| FR3134312A1 (en) | Yeast Cell Wall Extract Saccharomyces Cerevisiae Rich in -Glucans in the Prevention of Toxic Effects of the Mycotoxin Deoxynivalenol (DON) | |
| EP3600370B1 (en) | Use of copaifera oleoresin in pathologies of the prostate | |
| FR3026643A1 (en) | SUPPLEMENTARY FOOD BASED ON AROMATIC PLANT EXTRACTS FOR THE MANAGEMENT OF DIGITATED OR MORTELLARO DERMATITIS BY ABIOTIC STRESS MANAGEMENT | |
| WO2020260500A1 (en) | Combination product for helping maintain the natural defenses of the organism | |
| FR2991181A1 (en) | Composition, useful for inhibiting intestinal absorption of sugar and for treating metabolic syndrome and diabetes, and as a medicament or dietetic product against weight gain, comprises an aqueous extract of Boscia senegalensis | |
| FR2887456A1 (en) | "COMPOSITION FOR THE TREATMENT OF THE SUMMER DERMITE" | |
| FR2663543A1 (en) | HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21801933 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21801933 Country of ref document: EP Kind code of ref document: A1 |